跳至主要内容

Electrochemical deposition of dopamine–hyaluronic acid conjugates for anti-biofouling bioelectrodes

文献作者:Semin Kim, Yohan Jang, Lindy K. Jang, Sung Hyuk Sunwoo, Tae-il Kim, Seung-Woo Cho and Jae Young Lee   《Journal of Materials Chemistry B》


ABSTRACTS
Bioelectrodes have been widely used to effectively mediate electrical signals with biological systems for various biomedical applications, such as biosensors and prosthetic probes. However, the electrical properties of bioelectrodes are frequently degraded in the biological milieu due to biofouling of bioelectrode surfaces. Hence, the development of simple and effective strategies for bioelectrode surface modification is important for the mitigation of biofouling. To this end, we electrochemically modify electrodes with dopamine-conjugated hyaluronic acid (DA–HA); the modified electrodes exhibit highly hydrophilic surfaces. In addition, the electrochemical impedance of the DA–HA-modified electrodes remains similar to those of bare electrodes. The DA–HA-modified electrodes showed reduced non-specific protein adsorption and minimal adhesion of fibroblasts. Our novel electrochemical passivation of electrodes using DA–HA will contribute to the further development of fouling-resistant and biocompatible bioelectrodes. The electrodeposition of DA–HA can also be potentially applied for general surface modification of other metallic and conducting materials for various applications.

SCREENSHOT

RELATED PRODUCTS
FITC-labeled hyaluronic acid binding peptide (FITC-HABP) was purchased from ChinaPeptides (China).
CHAINING
http://pubs.rsc.org/-/content/articlelanding/2017/tb/c7tb00028f/unauth#!divAbstract

评论

此博客中的热门博文

CAS:85466-18-8|Thymopoietin II (32-35)|RKDV

Contact: Liven Qian(钱叶华)-Custom Peptide Mobile: 13761298676(微信) Email:cps037@chinapeptides.net QQ:2880526724 ChinaPeptides Co., Ltd./强耀生物科技有限公司 Name Thymopoietin II (32-35) Code [85466-18-8] The alias Thymopoietin II (32-35) Sequence (single letter abbreviation) RKDV Sequence (three-letter abbreviation) H-Arg-Lys-Asp-Val-OH (trifluoroacetate salt) A basic description TP-4 and TP-3; shortest active thymopoietin II fragments described that exhibit potent immunoregulatory properties in vitro and in vivo. solubility The molecular weight 516.6 Chemical formula C21H40N8O7 The purity 80%,90%,95%,98%,99% Weight 1mg,5mg,10mg,50mg,100mg,1g Storage conditions Store at -20°C. Keep tightly closed. Store in a cool dry place. Number of Residues: 4 1-Letter Code: RKDV 3-Letter Code: Arg-Lys-Asp-Val Molecular weight (Mr): 516.6 g/mol Isoelectric point: 10.1 Net charge at pH 7.0: 1.0 Average hydrophilicity: 1.9 Ratio of hydrophilic residues / total number of residues...

β-Amyloid (1-42), human|DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA

Contact: Liven Qian(钱叶华)-Custom Peptide Mobile: 13761298676(微信) Email:cps037@chinapeptides.net QQ:2880526724 ChinaPeptides Co., Ltd./强耀生物科技有限公司   04010011526 β-Amyloid (1-42), human DAEFRHDSGYEVHHQKLVFFAEDV GSNKGAIIGLMVGGVVIA Number of Residues: 42 1-Letter Code: DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 3-Letter Code: Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala Molecular weight (Mr): 4513.12 g/mol Isoelectric point: 5.8 Net charge at pH 7.0: -1.7 Average hydrophilicity: -0.1 Ratio of hydrophilic residues / total number of residues: 31 %    Name beta-Amyloid (1-42), recombinant Code   The alias beta-Amyloid (1-42), recombinant Sequence (single letter abbreviation) DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA Sequence (three-letter abbreviation) H-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-...

The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels

文献作者:Mark Barbour, Rachel Wood, Shehla U.Hridi, Chelsey Wilson, Grant McKay, Trevor J.Bushell, Hui-Rong Jiang   《Journal of Neuroimmunology》 ABSTRACTS Experimental autoimmune encephalomyelitis  (EAE) mice were administered with murine anti-CD52  antibody  to investigate its therapeutic effect and whether the treatment modulates IL-33 and ST2 expression. EAE severity and  central nervous system  (CNS) inflammation were reduced following the treatment, which was accompanied by peripheral  T and B lymphocyte  depletion and reduced production of various  cytokines  including IL-33, while sST2 was increased. In spinal cords of EAE mice, while the number of IL-33 +  cells remained unchanged, the extracellular level of IL-33 protein was significantly reduced in anti-CD52 antibody treated mice compared with controls. Furthermore the number of ST2 +  cells in the spinal cord of treated EAE mice was  downregulated ...